We report the long-term follow-up of children transplanted with Treosulfan (TREO)-based conditioning in Germany and Austria. Nine centres reported a total of 109 transplantations. Patients were stratified according to the paediatric TRM risk score derived from the paediatric BMT registry (PRST) and compared with the historical transplant population of this registry. Underlying diseases were malignancies, immunodeficiencies, and haematologic and metabolic disorders. TREO total dose ranged from 21-42 g/m 2 . Additional conditioning drugs included fludarabine, thiotepa, melphalan, CY and/or TBI. EFS at 3 years for non-malignant and malignant diseases was 88% and 49%, respectively. Leukaemia patients in remission had a survival of 51% at 3 years; nonremission patients relapsed and died within 18 months. TRM and OS in the low-risk groups 0 and 1 were similar to PRST controls. TRM in the high-risk groups 2 and 3 was markedly lower (9% vs 28% and 13% vs 53%, respectively) than in the PRST group, but OS was similar.
INTRODUCTION
Treosulfan (TREO) is an antineoplastic alkylating agent that has been used since the 1980s for the treatment of various neoplasms and is licensed in several European countries for the therapy of ovarian carcinoma. Casper et al. 1 first used TREO as part of a conditioning regimen together with Fludarabine (FLU) for allogeneic transplantation in adults with lymphoid and myeloid malignancies. These patients were considered ineligible for standard BU or TBI-based conditioning because of high comorbidity. The good myeloablative activity and very favourable toxicity profile inspired many transplant studies. 2 In children, especially infants and patients with nonmalignant disease, there is a specific need for a conditioning regimen with low acute toxicity and few late effects. Therefore, TREO was explored increasingly in paediatric patients. [3] [4] [5] [6] [7] In general, the favourable properties of TREO, and especially the decreased acute toxicity have been confirmed in these paediatric reports. As we also observed an increasing use of TREO in paediatric patients in Germany and Austria during the last 4 years, we decided to perform a formal retrospective analysis of all patients transplanted between 2003 and 2009 and compare it wih a historical control cohort provided by the Paediatric Registry for Stem Cell Transplantation (PRST), which documents all paediatic transplantations in Austria, Switzerland and Germany.
PATIENTS AND METHODS Patients
All 30 paediatric transplant centres in Germany and Austria were asked to submit data on patients who had received TREO conditioning. Nine centres reported a total of 109 transplantations. The patients and/or their guardians gave informed consent for retrospective data analysis.
Data source
Clinical data were reported by the SCT centres and verified by on-site monitoring in the seven largest centres and/or by queries in all centres. Patients between 1 July 2003 and 30 November 2009 were included. Last follow-up for survival and EFS was documented 2 years after the last patient had been included.
To compare outcomes of TREO-treated patients with outcomes of the total transplanted paediatric population, TRM risk scores derived from the German-Austrian registry for paediatric SCTs PRST 8 were documented in all patients.
Statistical methods
The specific baseline variables evaluated included underlying disease, age, sex, source of the graft, donor type, dose of TREO and dose of additional chemotherapy. Outcome variables included OS, EFS, engraftment and cause of death. Events were relapse, secondary malignant neoplasm or death from any cause. Patients lost to follow-up were censored at the time of withdrawal. For analysing OS and EFS, the Kaplan-Meier method was used to estimate probabilities of survival. Differences in the distribution of individual parameters among patient subsets were analysed using the w 2 test for categorized variables. The Cox proportional hazards model was used to obtain the estimates and the 95% confidence interval of the relative risk for prognostic factors. The two-sided log-rank test was used for comparing survival curves. Cumulative incidence estimates were calculated for relapses and TRM with deaths as competing events. If not otherwise specified, data are given as median with range (x;y). All P-values are two sided and were considered significant when o0.05. Statistical analyses were conducted using the SAS programme (Version 9.1, Cary, NC, USA).
Previously published patients
Patients 21 and 36 with Shwachman-Diamond syndrome were previously described by Sauer et al. 3 Patients 18 to 32 were included in the retrospective European Group for Bone Marrow Transplantation (EBMT) analysis of paediatric leukaemia patients conditioned with TREO. 7 The two patients with IL-10 receptor deficiency were reported by Kotlarz and Beier et al.
9
Patients included in this analysis were presented in abstract form at the EBMT congress 2008 by Wachowiak et al., 10 the EBMT 2010 congress by Beier et al. 11 and in an EBMT 2012 meta-analysis of TREO conditioned patients by Poetschger et al.
12

RESULTS
Patients
Sixty-eight (62.4%) patients were male and 41 (37.6%) were female. Half were transplanted for a malignancy and the other half for nonmalignant disease ( Table 1 ). The complete paediatric age range was represented and nine infants o1 year old were included.
Stem cell source Patients received BM (48.6%, n ¼ 53), G-CSF-mobilized PBSC (45% n ¼ 49), cord blood (CB, n ¼ 2) or PBSC combined with CB (PBSC þ CB, n ¼ 2). In three patients, the stem cell source was not reported. Ten patients with Ewing sarcoma received an autologous graft (data not shown). The allogeneic donors were HLA-matched siblings (n ¼ 22), matched related (n ¼ 4), mismatched related (n ¼ 1), matched unrelated (n ¼ 56), partially mismatched (n ¼ 2), haploidentical (n ¼ 12), or combined haploidentical with CB (haploidentical þ CB, n ¼ 2) donors. For details see Tables 2 and 3 .
Conditioning regimens
The majority of patients received TREO 3 Â 12 g/m 2 (39.4%, median age 9.5 years) or 3 Â 14 g/m 2 (50.5%, median age 7.9 years) in combination with FLU 5 Â 30 mg/m 2 (37.6%) or 6 Â 30 mg/m 2 (29.4%). Eight patients received 3 Â 10 g/m 2 (median age 15.8 years), and one 17-year-old patient 3 Â 7 g/m 2 together with radioimmunotherapy. Either thiotepa or melphalan (MEL) was added in 40.3% or 28.5% of patients, respectively. Antithymocyte globulin (n ¼ 41), alemtuzumab (n ¼ 26), muronomab OKT3 (OKT-3) (n ¼ 14), and a combination of anti-thymocyte globulin and OKT3 (n ¼ 3) were used together with CSA ± MTX or mycophenolate mofetil (MMF) as GVHD prophylaxis (Tables 2  and 3 ). The reason why a specific TREO dose was chosen for a specific patient could not be clarified in this retrospective analysis.
Engraftment
All patients engrafted and reached a WBC count of 1000/mL median on day þ 20. A platelet count of 20. 000/mL was reached on day 17.5 (median). Three patients required a stem cell boost because of secondary cytopenia and three experienced secondary Table 2 . Treosulfan conditioning in children R Beier et al graft rejection: two patients with thalassaemia, one after a haploidentical and one after a combined haploidentical þ CB transplantation. One patient is alive with recurrent thalassaemia and one engrafted after a second, BU-and CY-based SCT, but died later from infectious complications. One patient with severe congenital neutropenia (Kostmann's disease) rejected, who is alive after a second SCT.
GVHD
Half of the allogeneic patients (47/99 ¼ 47%) developed grade I to IV and 15% (11/99) grade III and IV acute GVHD. Eleven patients developed grade III skin, one grade III gut, two grade IV gut, and one grade III liver aGVHD. Seven (7%) of the allogeneic patients developed limited chronic skin GVHD and only one extensive chronic GVHD 13, 14 (Tables 2 and 3 ).
Toxicity and TRM Toxicity was especially difficult to evaluate because of the retrospective nature of this analysis. Even in patients that were monitored on site, toxicity documentation was often incomplete. Altogether, it was our impression that mucosal and gastrointestinal toxicity was relatively mild. Hepatic toxicity manifested itself as mildly increased transaminases and hepatomegaly. Hepatic veno-occlusive disease (VOD) was seen in only 3 of the 109 patients (2.8%). All had myeloid malignancy and an additional alkylator, either thiotepa or MEL, in their conditioning regimens. Skin toxicity with diaper rashes and sometimes perineal ulcers in infants were a common feature, but high-grade (IV) skin toxicity occurred only in four patients. The only patients in whom the conditioning regimen may have contributed to grade IV pulmonary toxicity were patient number 36, a 1.5-year-old child with Shwachman-Diamond syndrome, and patient number 25, a 12-year-old patient with Down's syndrome and ALL. Both had additional MEL in their conditioning regimens. Neurological symptoms during the course of HSCT were reported in 10 patients. Two patients had pre-existing conditions, one (patient 28) headaches and one (patient 39) vincristin neuropathy. Two had cerebral aspergillosis (patients 41 and 49). Four patients had seizures after HSCT (patients 30, 45, 65 and 72), two of them showed posterior leukoencephalopathy on MRI. Two patients (12 and 25) developed neurological symptoms in the course of terminal septic multi-organ failure.
Cardiac toxicity was reported in patient number 36 who developed right ventricular hypertrophy secondary to pulmonary hypertension. Patient number 55 had pericarditis and arterial hypertension and patient number 50 had pre-existing WolffParkinson-White (WPW)-syndrome and arterial hypertension. Heart failure was a part of terminal multi-organ failure in patients 12, 25, 36, 49 and 52.
Three of the nine infants o1 year of age developed grade III or higher toxicity. Patient number 72 (TREO 42 g, thiotepa 8 mg/kg) had a seizure during treatment with anti-thymocyte globulin. Patient number 24 (36 g TREO, 4 mg/kg MEL) developed increased right ventricular pressure and was treated as pulmonary VOD, which resolved after defibrotide and sildenafil. Patient number 110 (36 g TREO) died from respiratory failure of presumed infectious origin; parainfluenza III, HHV-6 and pneumocystis were isolated from his lungs.
In summary, it was not possible to attribute toxicity to any specific element of the myeloablative-immunosuppressive regimen, to pre-existing morbidity, or the underlying disease. Most patients with high-grade toxicity had received multiple alkylators. No high-grade toxicity was seen in patients receiving only TREO and FLU, except two (31 and 110). Most neurological and cardiac symptoms could be explained by common BMT complications like infection or calcineurin inhibitor toxicity. 
No data Died 2 months after Tx
Treosulfan conditioning in children R Beier et al Table 3 . Patient numbers were too low to answer the question of whether toxicity was more common in infants than in older children.
TRM was seen in 13/109 patients (11.9%). Of these, six had malignant and seven nonmalignant diseases. The patients with malignancies had high-risk disease, including ALL on a background of Down's syndrome, ALL in fourth CR, or AML in full relapse (Table 4) .
Two patients with immunodeficiency died of viral infections, the others from pulmonary and hepatic failure, respectively. One patient (patient number 36) with Shwachman-Diamond syndrome died from interstitial pneumonia of unknown origin (Table 2 ).
Survival and antileukemic activity Long-term survival in the nonmalignant group continued to be excellent with 88% at a median follow-up of 2.5 years. EFS was identical, indicating that events, including late events, are negligible in number (EFS data not shown). Survival in the malignant group was 49% reflecting the high percentage of high-risk patients in this group (Figure 1) . Almost all events occurred during the first 2 years after transplantation. During this time, the EFS curve always preceded the survival curve by several months, indicating that most events were followed by death (survival data not shown). The predominant cause of death in this patient group was relapse. This also indicated that in this selected group of high risk patients with leukaemia, further rescue therapy was either not available or not successful. In other words, SCT with TREO conditioning was used as the treatment of last resort in these patients.
Remission status was a strong predictor of survival; patients not in remission at the time of transplantation relapsed mostly within 6 months. The single patient (patient number 3) who relapsed after 1.6 years had AML with predominantly extramedullary disease (Figure 2) .
Of the 17 patients who did not have ALL or AML and received an allogeneic transplantation, 7 had myelodysplastic syndrome, one biphenotypic leukaemia, and the others solid tumours (Table 3 ). In this small group, survival was about 60% and not as dependent on remission status at transplantation. Survival and EFS curves were virtually superimposable (data not shown). This was certainly due to the nature of the underlying diseases and too short a follow-up for the prolonged relapse curve of these conditions. Paediatric patients can be stratified according to their risk of overall mortality and TRM by a score developed by MatthesMartin et al. 8 Multivariate analysis of paediatric transplants performed in Germany and Austria between 1989 and 2003 was performed on data from the PRST. It revealed a significant correlation of TRM with three risk factors: age 410 years, advanced disease and alternative donor. In this analysis, 1-year TRM vs OS were 5% vs 89% with a score of 0, 18% vs 74% with 1, 28% vs 54% with 2 and 53% vs 27% with 3 points. This TRM score also correlated with OS because patients with nonmalignant disease had a maximum score of 2 (no advanced disease) and patients with advanced disease, often in nonremission, had a high relapse incidence per se. Figure 3 shows the TRM of the TREO patients stratified according to this TRM risk score. The TRM of the whole group was 12% and the TRM of the high risk groups with scores 2 and 3 was only 9% and 13%, respectively. For comparison, the reported historical TRM of the total PRST score 2 and 3 patients was 28% and 53%, respectively (score 0 to 3 TRMs reported by Matthes-Martin et al. (TRM M-M), shown in boxes). Figure 4 shows a comparison of OS of the risk-stratified TREO groups with the total PRST groups. Survival of TREO patients in the different risk groups is very comparable to the total PRST cohort. This is caused by the higher relapse rate in the score 2 DISCUSSION TREO already has a track record in the transplantation of children. Greystoke et al. 4 transplanted 32 children with nonmalignant diseases with 32 or 46 g/m 2 of TREO and observed a high engraftment rate of 78% and an OS of 84% after a median followup of 417 days with little regimen-related toxicity. Frequent but mild dermatologic toxicity was noted. The patients were selected for TREO instead of BU conditioning because they were felt to be at high risk for regimen-related toxicity, especially pulmonary and hepatic (VOD) toxicity. Cutting et al.
5 observed a similarly low toxicity in 25 patients treated with TREO in combination with cyclophosphamide. Slatter et al. 6 reported a series of 70 children with immunodeficiency who received TREO in combination with either CY or FLU. 66% were infants o1 year of age, the median age was 8.5 months. Even in this population that had a high risk of toxicity after BU or MEL, TREO-based conditioning showed little toxicity except-again-skin toxicity. OS was 81%. VOD occurred only twice with CY. Considering that the rate of VOD after BUbased conditioning is about 20%, 15 hepatic toxicity was low. Compared with MEL-based conditioning, toxicity was also reduced. Bernardo et al. 16 described 20 patients (median age 13 years) with thalassaemia who were transplanted with a combination of FLU, TREO and thiotepa. Survival with low toxicity was 95% and the thalassaemia-free survival 85%. No VOD occurred in this population with a high propensity for hepatic complications.
In our series of patients with nonmalignant disease, survival of 88% after 3 years is clearly in the same range as that reported by the authors cited above. Also, the frequent mild skin toxicity and compared with BU reduced mucosal toxicity and the low rate of VOD were observed in our series.
As the PRST TRM score was derived from paediatric transplants performed in Germany and Austria between 1989 and 2003, it is based on the experience with mostly BU and TBI-based conditioning regimens. The percentage of paediatric transplants with TREO-based conditioning in Germany and Austria started to increase from 0.2% in 2003 to 11% in 2008 (data from the PRST). Therefore, we could compare our cohort of TREO patients with the overall cohort of registered patients receiving mostly non-TREObased regimens. A note of caution needs to be added as the PRST TRM score is based on transplantations performed between 1989 and 2003, while the TREO cohort was transplanted between 2003 and 2009. Also, TREO was initially only given to patients with high risk of TRM, ineligible to receive BU or TBI because of comorbidities, or because of second transplantations. Later, when the low acute toxicity of TREO conditioning regimens was appreciated, it's use was liberalized and it was also used more frequently for nonmalignant conditions. Nevertheless, the availability of this TRM score was the best way to compare outcomes in the presence of a variable composition of risks in the transplanted patient population. It confirms the clinical impression of low acute toxicity and low TRM in nonmalignant disease, but also in high-risk malignancy. Whether the antileukemic acitivity is similar to BU or TBI is unclear, as no comparative studies have been done. In the retrospective EBMT analysis of childhood haematological malignancies Wachowiak et al. 7 showed a survival of 41% in children with lymphoid and 73% with myeloid malignancies at 48 months with a non-relapse mortality (NRM) of 16%. The a priori risk composition of this patient population may have been lower than that of the patients reported here.
In adults, TREO showed good activity in AML, CML and myelodysplastic syndrome. 1, [17] [18] [19] There is experience with NHL 20 but little experience with ALL. Nemecek et al. 17 reported a series of patients conditioned with FLU and TREO; most were adults with myeloid malignancies. They found that this regimen was most suitable for patients with relatively low-risk disease in whom it afforded both low NRM and a high relapse-free survival of 88%. Relapsed or refractory AML were problematic because of a high relapse rate (up to 62%). Therefore, intensification with radiotherapy was discussed for further patients.
The behaviour of our paediatric group with malignancies appeared to be similar to this group-good activity in lower risk disease-but high relapse rate in high-risk malignancy even though many patients in our group had already received intensification by additional conditioning drugs. Other intensification regimens have been described. 21 In summary, we show that TREO-based regimens in children provide good engraftment with reduced toxicity, making them suitable for children with high risk of regimen-related toxicity. High-grade toxicity occurred mostly in patients receiving additional alkylating agents. Good long-term survival with few late events was seen in nonmalignant disease. TREO-regimens allowed high-risk patients with malignancies to reach the posttransplant phase with little regimen-related toxicity. Although survival was not improved in our high-risk population, these regimens make further interventions in the post-transplant period possible.
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